Literature DB >> 30244022

Dynorphin/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders.

Hugo A Tejeda1, Antonello Bonci2.   

Abstract

Negative affective states are prevalent symptoms in a plethora of neuropsychiatric disorders, including depression and drug addiction. Dysfunction of mesocorticolimbic dopamine systems has been implicated in negative affective states in neuropsychiatric disorders. The dynorphin/kappa-opioid receptor system is a powerful effector of stress-related behavior and is highly enriched within the mesocorticolimbic dopamine system. Dysfunction of dynorphin/KOR signaling within the mesocorticolimbic dopamine system is implicated in promoting symptoms in neuropsychiatric disorders. As such, the kappa-opioid receptor system provides an important therapeutic target to treat negative affective states associated with psychiatric disorders. In this review, we provide a comprehensive overview of the dynorphin/kappa-opioid receptor system and its role in regulating the mesocorticolimbic dopamine system, motivation, and emotional behavior. Furthermore, we highlight unresolved issues in the field and offer some insights for future research.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Year:  2018        PMID: 30244022     DOI: 10.1016/j.brainres.2018.09.023

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  27 in total

Review 1.  The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research.

Authors:  Matthew L Banks
Journal:  Handb Exp Pharmacol       Date:  2020

2.  Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration.

Authors:  E Andrew Townsend
Journal:  Psychopharmacology (Berl)       Date:  2021-01-06       Impact factor: 4.530

3.  Sex Differences in Escalated Methamphetamine Self-Administration and Altered Gene Expression Associated With Incubation of Methamphetamine Seeking.

Authors:  Atul P Daiwile; Subramaniam Jayanthi; Bruce Ladenheim; Michael T McCoy; Christie Brannock; Jennifer Schroeder; Jean Lud Cadet
Journal:  Int J Neuropsychopharmacol       Date:  2019-11-01       Impact factor: 5.176

Review 4.  Endogenous Opioids at the Intersection of Opioid Addiction, Pain, and Depression: The Search for a Precision Medicine Approach.

Authors:  Michael A Emery; Huda Akil
Journal:  Annu Rev Neurosci       Date:  2020-02-28       Impact factor: 12.449

Review 5.  Dopaminergic cellular and circuit contributions to kappa opioid receptor mediated aversion.

Authors:  Elyssa B Margolis; Anushree N Karkhanis
Journal:  Neurochem Int       Date:  2019-07-10       Impact factor: 3.921

6.  Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates.

Authors:  Mei-Chuan Ko; Stephen M Husbands
Journal:  Handb Exp Pharmacol       Date:  2020-12-04

7.  Kappa Opioid Receptors Drive a Tonic Aversive Component of Chronic Pain.

Authors:  Shiwei Steve Liu; Sarah Pickens; Nicole E Burma; Ines Ibarra-Lecue; Hongyan Yang; Lihua Xue; Chris Cook; Joshua K Hakimian; Amie L Severino; Lindsay Lueptow; Kristina Komarek; Anna M W Taylor; Mary C Olmstead; F Ivy Carroll; Caroline E Bass; Anne M Andrews; Wendy Walwyn; Tuan Trang; Christopher J Evans; Frances M Leslie; Catherine M Cahill
Journal:  J Neurosci       Date:  2019-03-12       Impact factor: 6.167

8.  Kappa opioid receptor modulation of excitatory drive onto nucleus accumbens fast-spiking interneurons.

Authors:  Benjamin C Coleman; Kevin M Manz; Brad A Grueter
Journal:  Neuropsychopharmacology       Date:  2021-08-16       Impact factor: 7.853

9.  Cocaine Dysregulates Dynorphin Modulation of Inhibitory Neurotransmission in the Ventral Pallidum in a Cell-Type-Specific Manner.

Authors:  Kineret Inbar; Liran A Levi; Nimrod Bernat; Tal Odesser; Dorrit Inbar; Yonatan M Kupchik
Journal:  J Neurosci       Date:  2019-12-13       Impact factor: 6.167

Review 10.  Translational value of non-human primates in opioid research.

Authors:  Huiping Ding; Mei-Chuan Ko
Journal:  Exp Neurol       Date:  2021-01-14       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.